Hamburg / Dassow, November 20, 2020

AqVida is still able to deliver on the cancer drug epirubicin.

The cytostatics manufacturer has been producing the product in its own production facility for oncology products in Northwest Mecklenburg since the beginning of 2020. The AqVida production facility, which went into operation in 2016, is equipped with state-of-the-art robot technology. The company produces concentrates for cancer therapy at its Dassow location in Mecklenburg-Western Pomerania.

Among other things, the product epirubicin, for which delivery bottlenecks repeatedly occurred in 2020. The reasons for this were, among other things, a lack of raw material sources and the enormous price pressure that weighs on the product. "The low reimbursement prices of the health insurance companies push the price to a level that is no longer adequate for us as a German manufacturer," says Wolfgang Heinze, managing director at AqVida. However, due to the tense supply situation, AqVida decided to keep epirubicin in the standard portfolio. "Guaranteeing reliable delivery is our main concern," says Wolfgang Heinze. "Our partner pharmacies depend on providing the infusion solutions for the patients on time in order to achieve the greatest possible therapeutic success."

Thanks to flexible production processes and short distances, AqVida was able to maintain delivery capacity almost seamlessly through the whole of 2020.

We are available for current company topics and interview requests:

Saskia Heinze

Claudia Schubert

Telephone:

49 (0) 40 / 380 371 9 - 0

Mail: pr@aqvida.com